31.05.2019 - Haematologica 2018; 103:1298-307
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid
leukemia over a five-year period: final results of a phase I/II study
Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian,
Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin,
Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brummendorf and H. Jean Khoury. Haematologica 2018; 103:1298-1307